What changed: Glioma & glioblastoma
Every dated change on the records linked to Glioma & glioblastoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 2
- 2026-09-17This recordGlioma & glioblastomaFacts on this page last checked
When this page itself was last checked or edited.
- 2026-09-11RegulatoryFloretyrosine F-18 (FET)Floretyrosine F-18 (FET): approval (US)
Pixclara, NDA 218592 (Telix Pharmaceuticals US), original approval; FDA classification Type 1 new molecular entity
2026 · 2
- 2026ApprovalFloretyrosine F-18 (FET)Floretyrosine F-18 (FET) approved in US
Use with PET to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and paediatric patients 1 month of age and older
- 2026MilestoneGlioma & glioblastomaASCO 2026: NeoVax personalised vaccine immune responses; multi-target CAR-T; tovorafenib EU approval
A milestone in how this cancer is treated.
2025 · 1
2024 · 1
2023 · 1
2022 · 1
2021 · 1
2020 · 1
2017 · 1
2016 · 1
2015 · 1
2014 · 1
2009 · 1
2008 · 1
2005 · 2
1999 · 3
- 1999ApprovalTemozolomideTemozolomide approved in EU
Temodal; malignant glioma (recurrent 1999; newly diagnosed glioblastoma with radiotherapy 2005); 26 Jan 1999
- 1999ApprovalTemozolomideTemozolomide approved in US
Refractory anaplastic astrocytoma
- 1999MilestoneTemozolomideTemozolomide approved (anaplastic astrocytoma)
A milestone in how this cancer is treated.